Displaying drugs 1901 - 1925 of 1954 in total
AV608
AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Investigational
Dexloxiglumide
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.
Investigational
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
ATX-101
ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in...
Investigational
Matched Description: … As a naturally occurring component of the human body, deoxycholate is considered a ‘biocompatible’ detergent …
Sugemalimab
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational
Matched Description: … Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals …
Etizolam
Etizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class; it differs from BDZs in having a benzene ring replaced with a thiophene ring. It is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. Initially introduced in 1983...
Experimental
Bardoxolone
Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic oxidative stress. In contrast, Bardoxolone in...
Investigational
KP-1461
KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.
Investigational
Mavorixafor
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Investigational
Matched Description: … [L50642]
As CXCR4 mutations have also been implicated in human immunodeficiency virus (HIV), Waldenstrom …
TG4010
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory...
Investigational
Matched Description: … A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin …
Etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that …
Seletracetam
Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. It is predicted to have...
Investigational
Matched Description: … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing …
GTS-21
GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition...
Investigational
Matched Description: … acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human …
RG-7795
Investigational
Tirapazamine
Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia. Hence, tirapazamine is solely activated in those hypoxic areas of solid...
Investigational
Matched Description: … This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon …
Lintuzumab satetraxetan AC-225
Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).
Investigational
Dapirolizumab pegol
Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
Investigational
Doxofylline
Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does...
Experimental
Matched Description: … has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human …
Betula pendula tar oil
Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation and it...
Nutraceutical
Matched Description: … L2862] Under the EMA, betula pendula tar oil is approved under the category of herbal medicines for human …
SARS-CoV-2 mRNA vaccine
SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2 . It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd....
Investigational
Matched Description: … Preclinical studies in mice and non-human primates has shown that intramuscular administration of ARCoV …
Hydrocortisone aceponate
Experimental
Vet approved
Gam-COVID-Vac
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … Phase 1/2 human trials with 76 participants evaluated the safety, tolerability, and immunogenicity of …
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody …
Natural Killer Cell
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry...
Investigational
Matched Description: … These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral ... Induced pluripotent stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate …
Zanidatamab
According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to...
Investigational
Displaying drugs 1901 - 1925 of 1954 in total